Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol Immunother. 2008 Dec; 57(12):1817-25.

View in: PubMed

subject areas

Adjuvants, Immunologic
Breast Neoplasms
Cancer Vaccines
Dose-Response Relationship, Drug
Female
Granulocyte-Macrophage Colony-Stimulating Factor
HLA-A2 Antigen
HLA-A3 Antigen
Humans
Kaplan-Meier Estimate
Neoplasm Recurrence, Local
Prognosis
Receptor, ErbB-2
Vaccines, Subunit

authors with profiles

ELIZABETH ANN MITTENDORF